“Antibody tests like these will play a critical role in measuring a person’s vaccine-induced immune response,” Roche CEO Thomas Schinecker said in a news release.
The tests targets “antibodies that are directed against the region of the novel coronavirus known as the spike protein, specifically the area that enables the virus to bind to a host cell receptor, which is required for the virus to enter the host cell.”
Many current COVID-19 vaccine candidates aim to induce an antibody response against the spike protein, Roche said.
The tests produce results in about 18 minutes.
Read the full news release here.
More articles on supply chain:
First mass shipment of Pfizer’s COVID-19 vaccine arrives in US
Connecticut company gets gets $590M US loan for disposable vaccine injector
Cost the biggest barrier to widespread coronavirus testing, survey finds
